| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.01. | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.01. | Inspira Technologies: Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders | 1 | GlobeNewswire (USA) | ||
| 08.01. | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 08.01. | Inspira Technologies: Aktie steigt nach Bekanntgabe von Expansionsplänen im Bereich Flüssigbiopsie | 3 | Investing.com Deutsch | ||
| 08.01. | Inspira Technologies: Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion | 1 | GlobeNewswire (USA) | ||
| INSPIRA TECHNOLOGIES OXY BHN Aktie jetzt für 0€ handeln | |||||
| 06.01. | Inspira Technologies OXY B.H.N. Ltd - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 05.01. | Inspira Technologies: Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation | 1 | GlobeNewswire (USA) | ||
| 31.12.25 | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.12.25 | Inspira Technologies reaffirms $49.5 million in purchase orders | 3 | Investing.com | ||
| 23.12.25 | Inspira Technologies Reaffirms $49.5 Million in Binding Purchase Orders and Aligns Execution with 2026 Regulatory and Deployment Milestones | 298 | GlobeNewswire (Europe) | RA'ANANA, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies... ► Artikel lesen | |
| 23.12.25 | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 22.12.25 | Inspira Technologies OXY B.H.N. Ltd - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 15.12.25 | Inspira Technologies: Inspira Announces $1.8 Million Registered Direct Offering Priced At-The-Market and Additional Equity Financing Agreement to Support Ongoing Commercial Execution | 1 | GlobeNewswire (USA) | ||
| 15.12.25 | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 09.12.25 | Inspira Technologies secures Japanese patent for dual lumen cannula | 2 | Investing.com | ||
| 09.12.25 | Inspira Technologies Granted Patent in Japan for the INSPIRA ART System's Convertible Dual Lumen Cannula Device and Method of Use | 8 | GlobeNewswire (USA) | ||
| 03.12.25 | Inspira Technologies Announces Strategic Leap in Lab Capabilities - Accelerating Next-Generation Diagnostics and Blood Technology | 3 | GlobeNewswire (USA) | ||
| 03.12.25 | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 25.11.25 | Inspira Technologies OXY B.H.N. Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.11.25 | Inspira Technologies: Inspira Completes Clinical Study for HYLA Blood Sensor - Ahead of Regulatory Submission | 142 | GlobeNewswire (Europe) | RA'ANANA, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 47,650 | -3,80 % | EQS-PVR: Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
26.01.2026 /... ► Artikel lesen | |
| UNITEDHEALTH | 246,20 | +0,02 % | UnitedHealth vor Zahlen: Darauf kommt es an | Die Berichtssaison in den USA nimmt peu à peu Fahrt auf. Am morgigen Dienstag wird der größte US-Krankenversicherer UnitedHealth vor US-Börseneröffnung die Zahlen für das vergangene vierte Quartal respektive... ► Artikel lesen | |
| MEDTRONIC | 84,41 | +0,02 % | Anteris Technologies Global Corp.: Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises | MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed... ► Artikel lesen | |
| GERRESHEIMER | 26,480 | +0,99 % | Gerresheimer-Aktie // Boden scheint gefunden | Eine beeindruckende Talfahrt erlebte die Gerresheimer-Aktie in den vergangenen Jahren. Nachdem im Herbst 2023 bei 122,90 Euro noch ein Rekordhoch erreicht worden war, ging es bis auf ein Zwischentief... ► Artikel lesen | |
| THERMO FISHER | 513,10 | +0,79 % | A Glimpse of Thermo Fisher Scientific's Earnings Potential | ||
| HIMS & HERS HEALTH | 24,040 | +0,12 % | Hims & Hers Scales Platform-Led Digital Healthcare Access and Care | ||
| BOSTON SCIENTIFIC | 78,20 | -0,51 % | Boston Scientific completes Nalu Medical acquisition | ||
| RESMED | 214,90 | -0,42 % | Resmed's Q2 Earnings on Deck: What's in Store for the Stock? | ||
| CARDINAL HEALTH | 178,50 | +1,36 % | Cardinal Health stock price target raised to $233 from $225 at TD Cowen | ||
| MCKESSON | 693,60 | +0,23 % | MARKTALARM: EchoIQ rettet Leben - Anerkennung kommt JETZT | ||
| OTTOBOCK | 63,00 | -1,87 % | UBS stuft Ottobock auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Ottobock mit einem Kursziel von 74 Euro auf "Neutral" belassen. Europas Medizintechnik-Branche stehe vor einem Revival,... ► Artikel lesen | |
| SOLVENTUM | 64,40 | +0,31 % | Solventum upgraded at KeyBanc on meeting long-term growth targets | ||
| ZIMMER BIOMET | 72,32 | +0,81 % | TD Cowen assumes coverage on Zimmer Biomet stock with Buy rating | ||
| CENTENE | 34,790 | -0,80 % | Centene (CNC) Loses 10% on Flat Medicare Funding | ||
| INSULET | 215,30 | 0,00 % | Cowen nimmt Insulet-Coverage mit 'Hold'-Rating auf |